NCT05264129: Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine |
|
|
| Completed | 4 | 263 | US | Atogepant, QULIPTA, Ubrogepant, UBRELVY | AbbVie | Episodic Migraine | 04/23 | 04/23 | | |
NCT06972056: Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study |
|
|
| Recruiting | 4 | 1335 | US | Atogepant 60 mg, Qulipta, Propranolol 160 mg, Inderal, Topiramate 100 mg, Topamax | Mayo Clinic, University of Iowa, Patient-Centered Outcomes Research Institute, AbbVie | Migraine | 03/29 | 12/29 | | |
